glp-1 news october 9 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford GLP-1 trends 2025: real-world data,

Diabetes leads to a significantly accelerated incidence of various related macrovascular complications, including peripheral vascular disease and cardiovascular disease (the most common cause of mortality in diabetes), as well as microvascular complications such as kidney disease and retinopathy

Aetna may cover Wegovy, Zepbound, and other weight loss injections if you meet BMI and prior authorization criteria

Issue 42 of The Altascientist explores GLP-1 receptor agonist drug development, covering preclinical models, bioanalytical assays, clinical study design, and manufacturing

Getting GLP-1 weight loss medication no longer requires traditional insurance coverage

Plant-based, designed to support energy and supports a healthy daily routine

Healthcare providers, pharmacies, and telehealth companies should view 2026 as a critical compliance inflection point.